Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 57, Issue 12, Pages 1949-1956Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.116.179234
Keywords
gastroenteropancreatic neuroendocrine tumors (GEP NETs); PET/CT; Ga-68-somatostatin analogues; F-18-FDOPA; F-18-FDG
Ask authors/readers for more resources
Through diagnostic imaging and peptide receptor radionuclide therapy, nuclear medicine has eamed a major role in gastroenteropancreatic neuroendocrine tumors (GEP NETs). GEP NETs are diagnosed fortuitously or on the basis of symptoms or hormonal syndrome. The functional tumor characteristics shown by radionuclide imaging allow for more accurate staging and treatment selection. Tumor grade helps determine which tracer should be selected. In the past, (111)ln-pentetreotide has been successful in well-differentiated (G1 and G2) tumors. However, PET/CT imaging with novel somatostatin analogs (e.g., Ga-68-DOTATOC, Ga-68-DOTATATE, Ga-68-DOTANOC, and Cu-64-DOTATATE) now offers improved sensitivity. F-18-fluorodihydroxyphenylalanine (F-18-FDOPA) is another interesting radiopharmaceutical. F-18-FDOPA sensitivity is influenced by a tumor's capacity to take up, decarboxylate, and store amine precursors. F-18-FDOPA sensitivities are highest in ileal NETs and may also be helpful in insulinomas. A high uptake of F-18-FDG with a low uptake of somatostatin analog usually indicates poorly differentiated tumors (G3). Starting from these principles, this article discusses theranostic approaches to GEP NETs, taking into account both primary and metastatic lesions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available